Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BCX9930 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| BCX9930 | EXPERIMENTAL | Parts 1, 2 and 3 |
| Placebo | PLACEBO_COMPARATOR | Parts 1 and 2 only |
| Name | Type | Description |
|---|---|---|
| BCX9930 | DRUG | BCX9930 capsules for oral administration |
| Placebo | DRUG | placebo to match BCX9930 capsules for oral administration |
Key Inclusion Criteria (Parts 1, 2, and 3): * Able to provide written informed consent * Acceptable birth control measures for male subjects and women of childbearing potential * Is expected to adequately comply with required study procedures and restrictions Key Inclusion Criteria (Parts 1 and 2)...
BCX9930 is an investigational small molecule being developed for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH), a rare hematologic disorder. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
BCX9930 is being developed by BioCryst Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol BCRX. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug.
BCX9930 is in Phase 1 clinical development. A first-in-human study has been completed, and the drug remains investigational. It has not received regulatory approval and is not yet available for commercial use.
BCX9930 has one completed Phase 1 trial, identified as NCT04330534, titled "First-in-Human Study of BCX9930 in Healthy Volunteers and Patients With PNH." The study enrolled 168 participants across Austria, South Africa, and the United Kingdom.
No alternative names for BCX9930 have been reported. The drug is identified solely by its code name BCX9930 in clinical trial registries and scientific literature.